pharmacokinetics and toxicity of linezolid in MDR-TB patients

Phase 4

• Conditions: tuberculosis MDR-TB; 10028440

• Registration Number: NL-OMON29905
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

MDR-TB
attending physician initiates treatment with linezolid

Exclusion Criteria

allergy for linezolid

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>-Primary: PK of linezolid in MDR-TB patients</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>-Secondary: toxicity related to linezolid; i.e. anemia, and neurotoxicity</p><br>